Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.

ABSTRACT:

Background

Panobinostat is a histone deacetylase inhibitor with antineoplastic and antiangiogenic effects in glioma that may work synergistically with bevacizumab. We conducted a multicenter phase II trial of panobinostat combined with bevacizumab in patients with recurrent high-grade glioma (HGG).

Methods

Patients with recurrent HGG were treated with oral panobinostat 30 mg 3 times per week, every other week, in combination with bevacizumab 10 mg/kg every other week. The primary endpoint was a 6-month progression-fee survival (PFS6) rate for participants with recurrent glioblastoma (GBM). Patients with recurrent anaplastic glioma (AG) were evaluated as an exploratory arm of the study.

Results

At interim analysis, the GBM arm did not meet criteria for continued accrua

SUBMITTER: Lee EQ 

PROVIDER: S-EPMC4483124 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature